The cost-effectiveness of achieving asthma control with the combination products salmeterol/fluticasone propionate or formoterol/budesonide

M. J. Price, A. H. Briggs (Greenford, Oxford, United Kingdom)

Source: Annual Congress 2001 - Asthma treatment
Session: Asthma treatment
Session type: Poster Discussion
Number: 1075
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. J. Price, A. H. Briggs (Greenford, Oxford, United Kingdom). The cost-effectiveness of achieving asthma control with the combination products salmeterol/fluticasone propionate or formoterol/budesonide. Eur Respir J 2001; 16: Suppl. 31, 1075

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Initial maintenance therapy with fluticasone propionate/ salmeterol combination product provides superior asthma control versus montelukast or fluticasone propionate alone
Source: Eur Respir J 2002; 20: Suppl. 38, 386s
Year: 2002

The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD
Source: Eur Respir J 2004; 24: Suppl. 48, 290s
Year: 2004

Achievement of total control of asthma in clinical practice using the combination of inhaled salmeterol and fluticasone propionate
Source: Eur Respir J 2006; 28: Suppl. 50, 616s
Year: 2006

The fluticasone/salmeterol combination product is superior to montelukast as first-line asthma control
Source: Eur Respir J 2001; 18: Suppl. 33, 263s
Year: 2001

Treatment effectiveness and exacerbations during one year with seretide compared to fluticasone propionate and salmeterol in mild-to-moderate asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 176s
Year: 2001

Fluticasone propionate/formoterol fumarate combination therapy is more effective than fluticasone propionate alone in the treatment of asthma
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010

A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD
Source: Eur Respir J 2014; 43: 763-772
Year: 2014



Aiming for total control of asthma with salmeterol/fluticasone propionate (SFC), a cost effective option
Source: Eur Respir J 2005; 26: Suppl. 49, 430s
Year: 2005

Combination therapy with salmeterol and fluticasone propionate (SFC) is more effective than salmeterol (SAL) alone in reducing exacerbations of COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 292s
Year: 2005

Efficacy of salmeterol/fluticasone propionate combination administered via Diskus inhaler in children with asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 429s
Year: 2002

Efficacy of salmeterol/fluticasone propionate MDI versus higher dose fluticasone propionate in adolescent and adult asthmatics uncontrolled on fluticasone propionate alone
Source: Eur Respir J 2003; 22: Suppl. 45, 438s
Year: 2003

Cost-effectiveness of budesonide and formoterol in a single inhaler compared to fluticasone in the treatment of asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 157s
Year: 2001

Fluticasone propionate/formoterol fumarate combination therapy is as effective as fluticasone propionate/salmeterol xinafoate, but has a more rapid onset of action in the treatment of asthma
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010

Efficacy and safety of fluticasone/formoterol compared to fluticasone alone in patients with asthma
Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD
Year: 2012

Efficacy and safety of ciclesonide compared with fluticasone propionate or budesonide in adolescent patients with persistent asthma
Source: Eur Respir J 2007; 30: Suppl. 51, 458s
Year: 2007

Fluticasone propionate/formoterol fumarate (FLUT/FORM) combination therapy has comparable efficacy to fluticasone propionate/salmeterol xinafoate (FLUT/SAL) in paediatric patients with asthma
Source: Annual Congress 2011 - Treating childhood asthma
Year: 2011


Long-term clinical management with the salmeterol/fluticasone propionate combination, fluticasone propionate and sameterol in a 'real-life' study
Source: Eur Respir J 2003; 22: Suppl. 45, 236s
Year: 2003

Maintenance plus as-needed budesonide/formoterol is cost-effective compared with dose-titrated salmeterol/fluticasone
Source: Eur Respir J 2005; 26: Suppl. 49, 50s
Year: 2005

Efficacy of combination fluticasone furoate/vilanterol (FF/VI) and salmeterol/fluticasone propionate (SFC) over 12 weeks in patients with COPD
Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Year: 2012

Economic evaluation of salmeterol/fluticasone propionate combination vs budesonide/formoterol in Spain
Source: Annual Congress 2003 - Management of asthma in primary care
Year: 2003